XNCR earnings analysis
What we found in XNCR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Xencor reported a substantial decline in revenue and increased operational losses in Q1 2026. Total revenue dropped to $4.5 million, a decrease of $28.2 million compared to Q1 2025, while operating expenses rose to $82.4 million, leading to a significant loss of $128.6 million. Management highlighted lower milestone receipts and increased R&D expenditures as key drivers of the results.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Decline
- Total revenue decreased by $28.2 million to $4.5 million from $32.7 million in Q1 2025.
- Higher Operating Expenses
- Operating expenses rose to $82.4 million, up $6.5 million from $75.9 million in Q1 2025.
- Increased Net Loss
- Net loss for the quarter expanded to $128.6 million from $48.3 million in Q1 2025.
- R&D Expense Increase
- Research and development costs increased by $6.1 million to $64.7 million compared to $58.6 million in Q1 2025.
- Cash Burn Rate Up
- Cash flow used in operating activities was $67.6 million, a significant increase from $16.2 million in Q1 2025.
- End of Period Cash Reserves
- Cash, cash equivalents, and marketable securities fell to $541.8 million from $610.8 million as of December 31, 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Surging Net Loss
- Net loss for Q1 2026 reached $128.6 million, up from $48.3 million in Q1 2025, indicating rising financial distress.
- Decreased Cash Reserves
- Cash, cash equivalents, and marketable securities decreased by $69 million from $610.8 million at year-end 2025.
- Operational Dependency Risks
- Total revenues heavily reliant on milestone and royalty payments, which are uncertain and volatile.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.71
What they said about what is next.
Management has lowered revenue guidance for 2026 to $80 million to $90 million, consistent with previous estimates.
The filing reads worse than the one before it.
What came before.
- 10-K · February 25, 2026
- Xencor describes a platform-led strategy to advance XmAb engineered Fc domains and multi‑specific antibodies across oncology and autoimmune indications, growing revenues via milestone and royalty receipts while…
- 10-Q · November 5, 2025
- Xencor reported Q3 revenue of $20.999 million (up from $17.796 million a year ago) and GAAP net loss per share of $(0.08), materially narrower than $(0.72) in Q3 2024. Operating loss improved to $(47.519) million from…
- 10-Q · May 7, 2025
- Xencor reported Q1 2025 revenue of $32.7M, up 104.6% versus Q1 2024 ($16.0M) driven by milestone and royalty recognition, but remains unprofitable with an operating loss of $43.2M and diluted EPS of $(0.66). Liquidity…
- 10-Q · August 5, 2024
- Xencor reported Q2 revenue of $16,960 (in thousands), up sequentially from $12,805 (Q1) but down sharply year-over-year from $45,523. Operating loss widened to $(62,317) and GAAP net loss attributable to Xencor was…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XNCR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever